 Monoclonal antibodies, MABS, against the envelope, E, protein of Zika virus, ZIKV, have shown great potential as therapeutics against the Zika epidemic. However, these MABS can cause severe infections if they are used as a therapy due to antibody dependent enhancement of infection, ADE. To address this issue, researchers developed a broadly neutralizing flavivirus MAB, ZV1, with an identical protein backbone but different FC glycosylation profiles. Three glycoprotein variants were produced using wild type, WT, Chinese hamster ovary cells, CHO, or Nicosiana benthomiana plants, Nicosiana. These MABS were tested for their ability to neutralize ZIKV and Dengue virus, DNV, infection. The results showed that the WT and CHO MABS had similar neutralization potencies against both ZIKV and DNV, while the Nicosiana variant had no ADE activity. Additionally, the Nicosiana variant had higher ADCC activity than the other two MABS. In vivo testing showed, This article was authored by Mingyang, Haiyang Sun, Huafanlai, and others. We are article.tv, links in the description below.